Cancer Biotherapy and Radiopharmaceuticals
Journal Title
- Cancer Biotherapy and Radiopharmaceuticals
ISSN
- E 1557-8852 | P 1084-9785 | 1084-9785 | 1557-8852
Publisher
- Mary Ann Liebert Inc.
- Mary Ann Liebert
Listed on(Coverage)
| JCR | 1997-2019 |
|---|---|
| SJR | 1999-2019 |
| CiteScore | 2011-2019 |
| SCI | 2010-2019 |
| SCIE | 2010-2021 |
| CC | 2016-2021 |
| SCOPUS | 2017-2020 |
| MEDLINE | 2016-2021 |
| EMBASE | 2016-2020 |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- USA
Aime & Scopes
- Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Cancer Biotherapy and Radiopharmaceuticals coverage includes: /// Antibody drug conjugates /// Fusion toxins and immunotoxins /// Nanoparticle therapy /// Vascular therapy /// Inhibitors of proliferation signaling pathways